Mueller Grace D, Conway Shannon J, Gibeau Asumi, Shaikh Nader
Division of General Academic Pediatrics, Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Acta Paediatr. 2025 Mar;114(3):479-486. doi: 10.1111/apa.17546. Epub 2024 Dec 17.
To determine if short- (2-5 days) course antimicrobials are as effective as standard- (6-14 days) course antimicrobials in the treatment of symptomatic UTI in children.
MEDLINE and EMBASE were searched from their origin to January 2024. We only considered randomised controlled trials in children <18 years of age. The main outcomes of interest were UTI or bacteriuria at the end of therapy.
Nine studies were included. Compared to children treated with a standard course of antimicrobials, those treated with shortened courses of antimicrobials did not have significantly different risks of UTI at the end of therapy (risk difference 2.2%, CI: 0.0-4.3). Risk of bacteriuria at end of therapy (RD = 8.7%, CI: 5.3-12.2) was slightly higher in children treated with shorter courses. In children with fever at baseline (two studies), there was no significant difference in risk between short and standard duration treatment (RD = 0.4%, CI: -2.8 to 3.6).
In children without fever at the time of presentation, treatment with shorter courses of antimicrobials appears reasonable. More studies of febrile children are needed before shorter courses could be recommended for febrile children.
确定短疗程(2 - 5天)抗菌药物在治疗儿童有症状性尿路感染时是否与标准疗程(6 - 14天)抗菌药物一样有效。
检索MEDLINE和EMBASE自创建至2024年1月的文献。我们仅纳入18岁以下儿童的随机对照试验。主要关注的结局是治疗结束时的尿路感染或菌尿症。
纳入9项研究。与接受标准疗程抗菌药物治疗的儿童相比,接受短疗程抗菌药物治疗的儿童在治疗结束时发生尿路感染的风险无显著差异(风险差2.2%,可信区间:0.0 - 4.3)。接受短疗程治疗的儿童在治疗结束时的菌尿症风险(风险差 = 8.7%,可信区间:5.3 - 12.2)略高。在基线时有发热的儿童中(两项研究),短疗程和标准疗程治疗的风险无显著差异(风险差 = 0.4%,可信区间:-2.8至3.6)。
对于就诊时无发热的儿童,采用短疗程抗菌药物治疗似乎是合理的。在能够推荐对发热儿童采用短疗程治疗之前,还需要对发热儿童进行更多研究。